Literature DB >> 20486926

Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.

Marc Lavielle1, Adeline Samson, Ana Karina Fermin, France Mentré.   

Abstract

HIV dynamics studies, based on differential equations, have significantly improved the knowledge on HIV infection. While first studies used simplified short-term dynamic models, recent works considered more complex long-term models combined with a global analysis of whole patient data based on nonlinear mixed models, increasing the accuracy of the HIV dynamic analysis. However statistical issues remain, given the complexity of the problem. We proposed to use the SAEM (stochastic approximation expectation-maximization) algorithm, a powerful maximum likelihood estimation algorithm, to analyze simultaneously the HIV viral load decrease and the CD4 increase in patients using a long-term HIV dynamic system. We applied the proposed methodology to the prospective COPHAR2-ANRS 111 trial. Very satisfactory results were obtained with a model with latent CD4 cells defined with five differential equations. One parameter was fixed, the 10 remaining parameters (eight with between-patient variability) of this model were well estimated. We showed that the efficacy of nelfinavir was reduced compared to indinavir and lopinavir.
© 2010, The International Biometric Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20486926      PMCID: PMC3173750          DOI: 10.1111/j.1541-0420.2010.01422.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  24 in total

Review 1.  Modelling viral and immune system dynamics.

Authors:  Alan S Perelson
Journal:  Nat Rev Immunol       Date:  2002-01       Impact factor: 53.106

2.  Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells.

Authors:  G A Funk; M Fischer; B Joos; M Opravil; H F Günthard; B Ledergerber; S Bonhoeffer
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

3.  Mixed effects models with censored data with application to HIV RNA levels.

Authors:  J P Hughes
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

4.  Practical identifiability of HIV dynamics models.

Authors:  J Guedj; R Thiébaut; D Commenges
Journal:  Bull Math Biol       Date:  2007-06-08       Impact factor: 1.758

5.  Parameter identifiability and estimation of HIV/AIDS dynamic models.

Authors:  Hulin Wu; Haihong Zhu; Hongyu Miao; Alan S Perelson
Journal:  Bull Math Biol       Date:  2008-02-05       Impact factor: 1.758

6.  A Note on Conditional AIC for Linear Mixed-Effects Models.

Authors:  Hua Liang; Hulin Wu; Guohua Zou
Journal:  Biometrika       Date:  2008       Impact factor: 2.445

7.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis.

Authors:  B Ramratnam; S Bonhoeffer; J Binley; A Hurley; L Zhang; J E Mittler; M Markowitz; J P Moore; A S Perelson; D D Ho
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

Review 8.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

9.  Estimation of dynamical model parameters taking into account undetectable marker values.

Authors:  Rodolphe Thiébaut; Jérémie Guedj; Hélène Jacqmin-Gadda; Geneviève Chêne; Pascale Trimoulet; Didier Neau; Daniel Commenges
Journal:  BMC Med Res Methodol       Date:  2006-08-01       Impact factor: 4.615

10.  Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection.

Authors:  Rodolphe Thiébaut; Hélène Jacqmin-Gadda; Abdel Babiker; Daniel Commenges
Journal:  Stat Med       Date:  2005-01-15       Impact factor: 2.373

View more
  11 in total

Review 1.  Clinical pharmacology = disease progression + drug action.

Authors:  Nick Holford
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations.

Authors:  Chihiro Hasegawa; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-05-26       Impact factor: 2.745

3.  Mixed-Effects Models with Skewed Distributions for Time-Varying Decay Rate in HIV Dynamics.

Authors:  Ren Chen; Yangxin Huang
Journal:  Commun Stat Simul Comput       Date:  2014-06-23       Impact factor: 1.118

4.  Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.

Authors:  C Bazzoli; H Bénech; E Rey; S Retout; D Salmon; X Duval; J M Tréluyer; F Mentré
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Authors:  Daniel Röshammar; Ulrika S H Simonsson; Håkan Ekvall; Leo Flamholc; Vidar Ormaasen; Jan Vesterbacka; Eva Wallmark; Michael Ashton; Magnus Gisslén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-02       Impact factor: 2.745

6.  Simultaneous Bayesian inference for skew-normal semiparametric nonlinear mixed-effects models with covariate measurement errors.

Authors:  Yangxin Huang; Getachew A Dagne
Journal:  Bayesian Anal       Date:  2011-03-11       Impact factor: 3.728

7.  Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study.

Authors:  Mélanie Prague; Daniel Commenges; Jon Michael Gran; Bruno Ledergerber; Jim Young; Hansjakob Furrer; Rodolphe Thiébaut
Journal:  Biometrics       Date:  2016-07-26       Impact factor: 2.571

8.  Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase.

Authors:  Jing Li; Seongho Kim; Anthony F Shields; Kirk A Douglas; Christopher I McHugh; Jawana M Lawhorn-Crews; Jianmei Wu; Thomas J Mangner; Patricia M LoRusso
Journal:  J Clin Pharmacol       Date:  2016-11       Impact factor: 3.126

9.  Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Bernard Sébastien; Jérémie Guedj
Journal:  Biometrics       Date:  2016-05-05       Impact factor: 2.571

Review 10.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.